- Legend Biotech CEO abruptly steps down without permanent replacementIn a sudden leadership shift, Legend Biotech announced that its CEO, Ying Huang, Ph.D., resigned on Friday, with no permanent replacement yet named.Fierce Biotech · 1d ago↗ source
- From confidence to capital: Positioning biotech for the next growth cycleHow can biotechs be investor ready? Key takeaways from BIO International and DIA China 2026.BioPharma Dive · 1d ago↗ source
- Argenx acquires Forte for $2.2B to get hands on phase 2-stage vitiligo drugArgenx is spending $2.2 billion to absorb Forte Biosciences for its phase 2-stage vitiligo and celiac disease drug.Fierce Biotech · 1d ago↗ source